Benzodiazepines (BZDs) are a widely prescribed class of sedative-hypnotics compounds for the treatment of a broad range of conditions as anxiety and obsessive-compulsive disorders, phobias, sleep-related problems associated with insomnia, and for the management of alcohol and GHB withdrawal. zolpidem, zopiclone and zaleplon, commonly known as Z-drugs, are non-benzodiazepine hypnotic drugs with pharmacology similar to BDZs. despite their usefulness, BDZs and Z-drugs present a potential for abuse and dependence. moreover, the non-medical use of BDZs is a well-known phenomenon and represents an increasingly widespread public health problem since it is associated with an elevated risk of serious health consequences or fatal overdose, especially among specific group of users. The spectrum of BDZs and Z-drugs misuse is extended by new synthetic BDZs, which may pose high risks to users, since the majority have never undergone clinical trials or tests and consequently their pharmacology and toxicology are largely unknown.

Zaami, S., Graziano, S., Tittarelli, R., Beck, R., Marinelli, E. (2021). BDZs, designer BDZs, and Z-drugs: pharmacology and misuse insights. CURRENT PHARMACEUTICAL DESIGN, 27(15), 1221-1229 [10.2174/1381612827666210917145636].

BDZs, designer BDZs, and Z-drugs: pharmacology and misuse insights

Roberta Tittarelli;
2021-09-17

Abstract

Benzodiazepines (BZDs) are a widely prescribed class of sedative-hypnotics compounds for the treatment of a broad range of conditions as anxiety and obsessive-compulsive disorders, phobias, sleep-related problems associated with insomnia, and for the management of alcohol and GHB withdrawal. zolpidem, zopiclone and zaleplon, commonly known as Z-drugs, are non-benzodiazepine hypnotic drugs with pharmacology similar to BDZs. despite their usefulness, BDZs and Z-drugs present a potential for abuse and dependence. moreover, the non-medical use of BDZs is a well-known phenomenon and represents an increasingly widespread public health problem since it is associated with an elevated risk of serious health consequences or fatal overdose, especially among specific group of users. The spectrum of BDZs and Z-drugs misuse is extended by new synthetic BDZs, which may pose high risks to users, since the majority have never undergone clinical trials or tests and consequently their pharmacology and toxicology are largely unknown.
17-set-2021
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/43
English
BDZs
Z-drugs
abuse
diversion
misuse
new BDZs
pharmacology
Zaami, S., Graziano, S., Tittarelli, R., Beck, R., Marinelli, E. (2021). BDZs, designer BDZs, and Z-drugs: pharmacology and misuse insights. CURRENT PHARMACEUTICAL DESIGN, 27(15), 1221-1229 [10.2174/1381612827666210917145636].
Zaami, S; Graziano, S; Tittarelli, R; Beck, R; Marinelli, E
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
BDZ, Designer BDZs and Z_drugs.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 1 MB
Formato Adobe PDF
1 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/378831
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact